Lupin Seeks Anti-Obesity Drug Alliances While Aiming For No.2 Spot In Diabetes

In-Licensing Dynamics Are Changing

In an interview with Scrip, Lupin’s MD Nilesh Gupta spoke about seeking alliances to address the anti-obesity market in India post a demand surge for Wegovy and Mounjaro, the company’s thrust into pharma-adjacent businesses, the limited impact so far of the Israel-Palestine conflict on Indian pharma and more.

Lupin Managing Director Nilesh Gupta
Nilesh Gupta, Managing Director, Is Setting New Horizons For Lupin • Source: Lupin Ltd

Lupin Limited has been adding touch points with patients over the past few years, entering pharmaceutical-adjacent areas like diagnostics and patient rehabilitation. Besides, it is now restructuring legacy businesses like Active Pharmaceutical Ingredients (APIs) while entering new verticals like contract development and manufacturing (CDM).

Scrip caught up with managing director Nilesh Gupta to understand the intent behind such moves and gauge the strategic direction...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip